

Publikationsliste 2004

Originalarbeiten

1. Audigé A, Schlaepfer E, Bonanomi A, Joller H, Knuchel MC, Weber M, Nadal D and Speck RF. HIV-1 does not provoke alteration of cytokine gene expression in lymphoid tissue after acute infection ex vivo. *J Immunol* 2004;172:2687-96.
2. Balajee SA, Weaver M, Imhof A, Gribskov J and Marr KA. *Aspergillus fumigatus* variant with decreased susceptibility to multiple antifungals. *Antimicrob Agents Chemother* 2004;48:1197-203.
3. Billick E, Seibert C, Pugach P, Ketas T, Trkola A, Endres MJ, Murgolo NJ, Coates E, Reyes GR, Baroudy BM, Sakmar TP, Moore JP and Kuhmann SE. The differential sensitivity of human and rhesus macaque CCR5 to small-molecule inhibitors of human immunodeficiency virus type 1 entry is explained by a single amino acid difference and suggests a mechanism of action for these inhibitors. *J Virol* 2004;78:4134-44.
4. Cabrera C, Cozzi-Lepri A, Phillips AN, Loveday C, Kirk O, Ait-Khaled M, Reiss P, Kjaer J, Ledergerber B, Lundgren JD, Clotet B and Ruiz L. Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study. *Antivir Ther* 2004;9:787-800.
5. Cho PS, Mueller NJ, Cameron AM, Cina RA, Coburn RC, Hettiaratchy S, Melendy E, Neville DM, Jr., Patience C, Fishman JA, Sachs DH and Huang CA. Risk factors for the development of posttransplant lymphoproliferative disorder in a large animal model. *Am J Transplant* 2004;4:1274-82.
6. Ciuffi A, Bleiber G, Munoz M, Martinez R, Loeuillet C, Rehr M, Fischer M, Gunthard HF, Oxenius A, Meylan P, Bonhoeffer S, Trono D and Telenti A. Entry and transcription as key determinants of differences in CD4 T-cell permissiveness to human immunodeficiency virus type 1 infection. *J Virol* 2004;78:10747-54.
7. d'Arminio A, Sabin CA, Phillips AN, Reiss P, Weber R, Kirk O, El-Sadr W, De Wit S, Mateu S, Petoumenos K, Dabis F, Pradier C, Morfeldt L, Lundgren JD and Friis-Moller N. Cardio- and cerebrovascular events in HIV-infected persons. *Aids* 2004;18:1811-7.
8. Dor FJ, Doucette KE, Mueller NJ, Wilkinson RA, Bajwa JA, McMorrow IM, Tseng YL, Kuwaki K, Houser SL, Fishman JA, Cooper DK and Huang CA. Posttransplant lymphoproliferative disease after allogeneic transplantation of the spleen in miniature swine. *Transplantation* 2004;78:286-91.
9. Felley C, Morris MA, Wonkam A, Hirschel B, Flepp M, Wolf K, Furrer H, Battegay M, Bernasconi E, Telenti A and Frossard JL. The role of CFTR and SPINK-1 mutations in pancreatic disorders in HIV-positive patients: a case-control study. *Aids* 2004;18:1521-7.

10. Fischer M, Joos B, Hirschel B, Bleiber G, Weber R and Gunthard HF. Cellular viral rebound after cessation of potent antiretroviral therapy predicted by levels of multiply spliced HIV-1 RNA encoding nef. *J Infect Dis* 2004;190:1979-88.
11. Fischer M, Joos B, Wong JK, Ott P, Opravil M, Hirschel B, Weber R and Gunthard HF. Attenuated and nonproductive viral transcription in the lymphatic tissue of HIV-1-infected patients receiving potent antiretroviral therapy. *J Infect Dis* 2004;189:273-85.
12. Giger B, Bonanomi A, Odermatt B, Ladell K, Speck RF, Kojic D, Berger C, Niggli FK and Nadal D. Human tonsillar tissue block cultures differ from autologous tonsillar cell suspension cultures in lymphocyte subset activation and cytokine gene expression. *J Immunol Methods* 2004;289:179-90.
13. Glaeser C, Grimm F, Mathis A, Weber R, Nadal D and Deplazes P. Detection and molecular characterization of *Cryptosporidium* spp. isolated from diarrheic children in Switzerland. *Pediatr Infect Dis J* 2004;23:359-61.
14. Glass TR, Young J, Vernazza PL, Rickenbach M, Weber R, Cavassini M, Hirschel B, Battegay M and Bucher HC. Is unsafe sexual behaviour increasing among HIV-infected individuals? *Aids* 2004;18:1707-14.
15. Hansjee N, Kaufmann G, Strub C, Weber R, Battegay M and Erb P. Persistent Apoptosis in HIV-1-Infected Individuals Receiving Potent Antiretroviral Therapy Is Associated With Poor Recovery of CD4 T Lymphocytes. *J Acquir Immune Defic Syndr* 2004;36:671-677.
16. Hasse B, Ledergerber B, Egger M, Flepp M, Bachmann S, Bernasconi E, Guyot S, Hirschel B, Weber R and Gunthard HF. Antiretroviral treatment and osteonecrosis in patients of the Swiss HIV Cohort Study: a nested case-control study. *AIDS Res Hum Retroviruses* 2004;20:909-15.
17. Hättenschwiler A, Furrer J, Gunthard HF and Schulthess G. Unexpected complication in an elderly lady suffering from rheumatoid arthritis. *Schweiz Rundsch Med Prax* 2004;93:372-6.
18. Hersberger M, Bonhoeffer S, Rampini SK, Opravil M, Marti-Jaun J, Telenti A, Hanseler E, Ledergerber B and Speck RF. CCTTT-repeat polymorphism of the inducible nitric oxide synthase is not associated with HIV pathogenesis. *Clin Exp Immunol* 2004;137:566-9.
19. Imhof A, Balajee SA, Fredricks DN, Englund JA and Marr KA. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. *Clin Infect Dis* 2004;39:743-6.
20. Karrer U, Wagner M, Sierro S, Oxenius A, Hengel H, Dumrese T, Freigang S, Koszinowski UH, Phillips RE and Klenerman P. Expansion of protective CD8+ T-cell responses driven by recombinant cytomegaloviruses. *J Virol* 2004;78:2255-64.
21. Kaufmann GR, Khanna N, Weber R, Perrin L, Furrer H, Cavassini M, Ledergerber B, Vernazza P, Bernasconi E, Rickenbach M, Hirschel B and

- Battegay M. Long-term virological response to multiple sequential regimens of highly active antiretroviral therapy for HIV infection. *Antivir Ther* 2004;9:263-74.
22. Keiser O, Taffe P, Zwahlen M, Battegay M, Bernasconi E, Weber R and Rickenbach M. All cause mortality in the Swiss HIV Cohort Study from 1990 to 2001 in comparison with the Swiss population. *Aids* 2004;18:1835-43.
 23. Kuwaki K, Knosalla C, Dor FJ, Gollackner B, Tseng YL, Houser S, Mueller N, Prabharasuth D, Alt A, Moran K, Cheng J, Behdad A, Sachs DH, Fishman JA, Schuurman HJ, Awwad M and Cooper DK. Suppression of natural and elicited antibodies in pig-to-baboon heart transplantation using a human anti-human CD154 mAb-based regimen. *Am J Transplant* 2004;4:363-72.
 24. Ledergerber B, Lundgren JD, Walker AS, Sabin C, Justice A, Reiss P, Mussini C, Wit F, d'Arminio Monforte A, Weber R, Fusco G, Staszewski S, Law M, Hogg R, Lampe F, Gill MJ, Castelli F and Phillips AN. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. *Lancet* 2004;364:51-62.
 25. Marchetti O, Bille J, Fluckiger U, Eggimann P, Ruef C, Garbino J, Calandra T, Glauser MP, Tauber MG and Pittet D. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. *Clin Infect Dis* 2004;38:311-20.
 26. Mocroft A, Gatell J, Reiss P, Ledergerber B, Kirk O, Vella S, Blaxhult A, Phillips AN and Lundgren J. Causes of death in HIV infection: the key determinant to define the clinical response to anti-HIV therapy. *Aids* 2004;18:2333-7.
 27. Mocroft A, Ledergerber B, Viard JP, Staszewski S, Murphy M, Chiesi A, Horban A, Hansen AB, Phillips AN and Lundgren JD. Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group. *J Infect Dis* 2004;190:1947-56.
 28. Mueller NJ, Kuwaki K, Dor FJ, Knosalla C, Gollackner B, Wilkinson RA, Sachs DH, Cooper DK and Fishman JA. Reduction of consumptive coagulopathy using porcine cytomegalovirus-free cardiac porcine grafts in pig-to-primate xenotransplantation. *Transplantation* 2004;78:1449-53.
 29. Mueller NJ, Livingston C, Knosalla C, Barth RN, Yamamoto S, Gollackner B, Dor FJ, Buhler L, Sachs DH, Yamada K, Cooper DK and Fishman JA. Activation of porcine cytomegalovirus, but not porcine lymphotropic herpesvirus, in pig-to-baboon xenotransplantation. *J Infect Dis* 2004;189:1628-33.
 30. Nucci M, Marr KA, Queiroz-Telles F, Martins CA, Trabasso P, Costa S, Voltarelli JC, Colombo AL, Imhof A, Pasquini R, Maiolino A, Souza CA and Anaissie E. Fusarium infection in hematopoietic stem cell transplant recipients. *Clin Infect Dis* 2004;38:1237-42.
 31. Opravil M, Baumann D, Chave JP, Furrer H, Calmy A, Bernasconi E, Blasko M, Vernazza P, Ledergerber B and Perrin L. Long-term efficacy after switch from protease inhibitor-containing highly active antiretroviral therapy to abacavir, lamivudine, and zidovudine. *Aids* 2004;18:2213-5.

32. Oxenius A, Price DA, Hersberger M, Schlaepfer E, Weber R, Weber M, Kundig TM, Boni J, Joller H, Phillips RE, Flepp M, Opravil M and Speck RF. HIV-specific cellular immune response is inversely correlated with disease progression as defined by decline of CD4+ T cells in relation to HIV RNA load. *J Infect Dis* 2004;189:1199-208.
33. Oxenius A, Price DA, Trkola A, Edwards C, Gostick E, Zhang HT, Easterbrook PJ, Tun T, Johnson A, Waters A, Holmes EC and Phillips RE. Loss of viral control in early HIV-1 infection is temporally associated with sequential escape from CD8+ T cell responses and decrease in HIV-1-specific CD4+ and CD8+ T cell frequencies. *J Infect Dis* 2004;190:713-21.
34. Phillips A, Ledergerber B, Lundgren J, Hogg R, d'Arminio Monforte A, Castelli F, Walker AS, Staszewski S, Dabis F, Gazzard B, Saag M, Petoumenos K, Johnson M, Scullard G, Gill J, James I, Fisher M, Mussini C, Klein M and Costagliola D. Nucleoside analogue use before and during highly active antiretroviral therapy and virus load rebound. *J Infect Dis* 2004;190:675-87.
35. Phillips AN, Ledergerber B, Horban A, Reiss P, Chiesi A, Kirk O, Mulchany F, Fisher M, Machala L and Lundgren JD. Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression. *Aids* 2004;18:1795-804.
36. Rusert P, Fischer M, Joos B, Leemann C, Kuster H, Flepp M, Bonhoeffer S, Gunthard HF and Trkola A. Quantification of infectious HIV-1 plasma viral load using a boosted in vitro infection protocol. *Virology* 2004;326:113-29.
37. Scherer A, Frater J, Oxenius A, Agudelo J, Price DA, Gunthard HF, Barnardo M, Perrin L, Hirschel B, Phillips RE and McLean AR. Quantifiable cytotoxic T lymphocyte responses and HLA-related risk of progression to AIDS. *Proc Natl Acad Sci U S A* 2004;101:12266-70.
38. Schlaepfer E, Audigé A, von Beust B, Manolova V, Weber M, Joller H, Bachmann MF, Kundig TM and Speck RF. CpG oligodeoxynucleotides block human immunodeficiency virus type 1 replication in human lymphoid tissue infected ex vivo. *J Virol* 2004;78:12344-54.
39. Sendi P, Schellenberg F, Ungsedhapand C, Kaufmann GR, Bucher HC, Weber R and Battegay M. Productivity costs and determinants of productivity in HIV-infected patients. *Clin Ther* 2004;26:791-800.
40. Sitbon O, Gressin V, Speich R, Macdonald PS, Opravil M, Cooper DA, Fourme T, Humbert M, Delfraissy JF and Simonneau G. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. *Am J Respir Crit Care Med* 2004;170:1212-7.
41. Strub C, Kaufmann GR, Flepp M, Egger M, Kahlert C, Cavassini M and Battegay M. Gynecomastia and potent antiretroviral therapy. *Aids* 2004;18:1347-9.
42. Trkola A, Kuster H, Leemann C, Oxenius A, Fagard C, Furrer H, Battegay M, Vernazza P, Bernasconi E, Weber R, Hirschel B, Bonhoeffer S and Gunthard HF. Humoral immunity to HIV-1: kinetics of antibody responses in chronic

- infection reflects capacity of immune system to improve viral set point. *Blood* 2004;104:1784-92.
43. Trojan A, Giger R, Rist N and Speck RF. Impaired CD8+ T-cell reactivity against viral antigens in cancer patients with solid tumors. *Infection* 2004;32:287-92.
 44. van der Ploeg JR, Giertsen E, Ludin B, Morgeli C, Zinkernagel AS and Gmur R. Quantitative detection of *Porphyromonas gingivalis* fimA genotypes in dental plaque. *FEMS Microbiol Lett* 2004;232:31-7.
 45. Wagels T, Amiet R, Battegay M, Guex AC, Opravil M and Vernazza PL. Predictive value of adherence in patients starting highly active antiretroviral treatment for HIV infection. *Swiss Med Wkly* 2004;134:678-80.
 46. Weber R, Christen L, Christen S, Tschopp S, Znoj H, Schneider C, Schmitt J, Opravil M, Gunthard HF and Ledergerber B. Effect of individual cognitive behaviour intervention on adherence to antiretroviral therapy: prospective randomized trial. *Antivir Ther* 2004;9:85-95.
 47. Yerly S, Gunthard HF, Fagard C, Joos B, Perneger TV, Hirschel B and Perrin L. Proviral HIV-DNA predicts viral rebound and viral setpoint after structured treatment interruptions. *Aids* 2004;18:1951-3.
 48. Yerly S, Jost S, Telenti A, Flepp M, Kaiser L, Chave JP, Vernazza P, Battegay M, Furrer H, Chanzy B, Burgisser P, Rickenbach M, Gebhardt M, Bernard MC, Perneger T, Hirschel B and Perrin L. Infrequent transmission of HIV-1 drug-resistant variants. *Antivir Ther* 2004;9:375-84.
 49. Young J, De Geest S, Spirig R, Flepp M, Rickenbach M, Furrer H, Bernasconi E, Hirschel B, Telenti A, Vernazza P, Battegay M and Bucher HC. Stable partnership and progression to AIDS or death in HIV infected patients receiving highly active antiretroviral therapy: Swiss HIV cohort study. *Bmj* 2004;328:15.
 50. Yust I, Fox Z, Burke M, Johnson A, Turner D, Mocroft A, Katlama C, Ledergerber B, Reiss P and Kirk O. Retinal and extraocular cytomegalovirus end-organ disease in HIV-infected patients in Europe: a EuroSIDA study, 1994-2001. *Eur J Clin Microbiol Infect Dis* 2004;23:550-9.
 51. Zellweger C, Opravil M, Bernasconi E, Cavassini M, Bucher HC, Schiffer V, Wagels T, Flepp M, Rickenbach M and Furrer H. Long-term safety of discontinuation of secondary prophylaxis against *Pneumocystis pneumonia*: prospective multicentre study. *Aids* 2004;18:2047-53.
 52. Zingg W, Renner-Schneiter EC, Pauli-Magnus C, Renner EL, van Overbeck J, Schlapfer E, Weber M, Weber R, Opravil M, Gottstein B and Speck RF. Alveolar echinococcosis of the liver in an adult with human immunodeficiency virus type-1 infection. *Infection* 2004;32:299-302.
 53. Zuber JP, Calmy A, Evison JM, Hasse B, Schiffer V, Wagels T, Nuesch R, Magenta L, Ledergerber B, Jenni R, Speich R and Opravil M. Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy. *Clin Infect Dis* 2004;38:1178-85.

Übersichtsartikel

54. Mueller NJ and Fishman JA. Herpesvirus infections in xenotransplantation: pathogenesis and approaches. *Xenotransplantation* 2004;11:486-90.
55. Ruef C. Central issues of prevention of nosocomial infections--status in 2004. *Ther Umsch* 2004;61:191-6.
56. Ruef C. Requirements for infection control during surgery. *Ther Umsch* 2004;61:211-5.
57. Ruef C. Prevention of nosocomial infections in the medical office. *Ther Umsch* 2004;61:217-22.
58. Ruef C. Immunization for hospital staff. *Curr Opin Infect Dis* 2004;17:335-9.
59. Ruef C. Epidemiology and clinical impact of glycopeptide resistance in *Staphylococcus aureus*. *Infection* 2004;32:315-27.
60. Trkola A. HIV-host interactions: vital to the virus and key to its inhibition. *Curr Opin Microbiol* 2004;7:555-9.

Guidelines

61. Kjaer J and Ledergerber B. HIV cohort collaborations: proposal for harmonization of data exchange. *Antivir Ther* 2004;9:631-3.
62. Vandamme AM, Sonnerborg A, Ait-Khaled M, Albert J, Asjo B, Bacheler L, Banhegyi D, Boucher C, Brun-Vezinet F, Camacho R, Clevenbergh P, Clumeck N, Dedes N, De Luca A, Doerr HW, Faudon JL, Gatti G, Gerstoft J, Hall WW, Hatzakis A, Hellmann N, Horban A, Lundgren JD, Kempf D, Miller M, Miller V, Myers TW, Nielsen C, Opravil M, Palmisano L, Perno CF, Phillips A, Pillay D, Pumarola T, Ruiz L, Salminen M, Schapiro J, Schmidt B, Schmit JC, Schuurman R, Shulze E, Soriano V, Staszewski S, Vella S, Youle M, Ziermann R and Perrin L. Updated European recommendations for the clinical use of HIV drug resistance testing. *Antivir Ther* 2004;9:829-48.

Editorials

63. Ruef C. Peripheral intravenous catheters-to change or not to change? *Infection* 2004;32:1.
64. Ruef C. Hospital public health--from the sideline to center of interest. *Ther Umsch* 2004;61:189-90.
65. Ruef C. Prosthetic joint infections-towards an improved outcome. *Infection* 2004;32:189.
66. Ruef C. A new influenza pandemic-unprepared for a big threat? *Infection* 2004;32:313-4.
67. Ruef C. Selective decontamination of the digestive tract--the risks of prevention. *Infection* 2004;32:255-6.

Andere Publikationen

68. Colombo C and Ruef C. HIV-Postexpositionsprophylaxe (PEP) - Management: Umsetzung in medizinischen Institutionen der Deutschschweiz - Ergebnisse einer Umfrage. BAG Bulletin 2004;356-361.
69. Colombo C and Ruef C. HIV post-exposure prophylaxis management: results of a survey of medical institutions in German-speaking Switzerland in 2000. Eurosurveillance Weekly 2004;8:
70. Flepp M and Ledergerber B. The Swiss HIV Cohort Study--multifaceted network supporting patient care as well as large international research projects. Ther Umsch 2004;61:635-8.
71. Opravil M, Zuber JP and Speich R. Reply to torre and pugliese. Clin Infect Dis 2004;39:1550.

Dissertationen

72. Müller MA. Postoperative sternale Wundinfektionen - eine Fall-Kontroll-Studie zur Untersuchung von Folgen und Kosten. Med. Diss. Zürich 2004.
73. Zingg W. Impact of an outbreak of Norovirus infection on hospital resources. Med. Diss. Zürich 2004.